-1200x645-800x430.jpg)
- Exclusive commercialisation agreement signed with TMSC Viet Nam
- First commercial partnership in South-East Asia
- Two-year contract valued at $530,000
- Felix Vietnam registration expected in August
Memphasys (ASX:MEM) has added to its global expansion with the signing of an exclusive commercialisation agreement with TMSC Vietnam for the sale and distribution of its unique Felix System.
Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.
This is the company’s first commercial partnership in South-East Asia and comes less than a week after Memphasys announced a major Middle East and North Africa (MENA) commercialisation partnership with International Technical Legacy (ITL) for its patented bio separation technology.
Marjan Mikel, chair of the Memphasys Commercialisation Committee, said the agreement is a meaningful step in the geographic diversification of Memphasys’ international distribution network.
Vietnam is one of Asia’s fastest-growing assisted reproductive technology markets, with the IVF sector estimated at US$141 million in 2023 and forecast to exceed US$200 million by 2029, driven by rising infertility rates, increasing healthcare investment and growing demand for premium fertility services.
“Vietnam is exactly the kind of market Felix was built for; a sophisticated, high-growth IVF sector that is actively looking for clinical tools that improve outcomes and reduce procedural complexity,” Mr Mikel said.
“TMSC Vietnam brings deep local knowledge in reproductive health and a genuine commitment to advancing fertility care in Vietnam. This agreement does not only open a new geography, it confirms our commercial model is globally scalable to new markets. We are looking forward to working alongside the TMSC Vietnam team to introduce Felix to Vietnamese clinicians and we are confident in the opportunity ahead.”
Mr Mikel said Vietnam has established itself as a regional IVF leader, with success rates comparable to leading centres in Europe and the United States, supported by highly trained clinicians and rapidly expanding fertility infrastructure across Hanoi and Ho Chi Minh City.
“Against this backdrop, demand for advanced sperm selection technologies such as Felix is expected to accelerate as clinics increasingly focus on improving IVF outcomes and laboratory efficiency.”
The two-year agreement has a total contracted value of $530,000, comprising $205,000 in year one and $325,000 in year two with contracted quarterly cartridge order growth to meet expected as Felix clinical adoption.
Truong Cam Van, director of TMSC Viet Nam, said Vietnam’s fertility sector is growing rapidly and clinicians there are actively seeking technologies that deliver better outcomes for patients.
“Felix addresses a genuine clinical need, it is a sophisticated, evidence-based platform that we believe will resonate strongly with IVF specialists across the country.
“We are proud to be bringing this technology to Vietnam and look forward to working closely with the Memphasys team to establish Felix as the standard of care for sperm preparation in Vietnamese fertility clinics.”
Full commercial sales are expected to commence following receipt of regulatory approval from the relevant Vietnamese health authorities.
MEM is up 20% to 0.6¢. Mkt cap $14.23M.
Join the discussion: See what HotCopper users are saying about Memphasys and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.